Document Detail


The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction.
MedLine Citation:
PMID:  23347150     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Vacuum erection devices (VEDs) have been approved in the United States since 1982 and offer a viable alternative to oral phosphodiesterase type 5 inhibitors (PDE5i), injections and transurethral suppositories. Studies have demonstrated efficacy in erectile dysfunction (ED) associated with a variety of conditions. More recently, this modality has been evaluated in initial phosphodiesterase inhibitor nonresponders as well as for post-prostatectomy penile rehabilitation.
AIM: This article provides a detailed overview of the history of VEDs, a review of the literature, and a concise description of their new applications in modern urological practice.
METHODS: A retrospective review of publications relevant to the field of VEDs.
MAIN OUTCOME MEASURES: Review of the historical milestones, evolution, and modern utilization of VEDs in modern urological protocols.
RESULTS: Studies have demonstrated efficacy in ED associated with a variety of conditions. Early penile rehabilitation after surgery for prostate cancer with the VED appears to improve erectile function and penile length. Adverse events are transient and not serious.
CONCLUSIONS: The VED has continued to show efficacy for treatment of ED due to various etiologies and should be considered an attractive second-line therapy. In select cases such post-prostatectomy penile rehabilitation, as well as in men who cannot use a PDE5i, the vacuum device should be considered first-line treatment.
Authors:
Daniel Brison; Allen Seftel; Hossein Sadeghi-Nejad
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-24
Journal Detail:
Title:  The journal of sexual medicine     Volume:  10     ISSN:  1743-6109     ISO Abbreviation:  J Sex Med     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-04     Completed Date:  2013-09-30     Revised Date:  2013-12-20    
Medline Journal Info:
Nlm Unique ID:  101230693     Medline TA:  J Sex Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1124-35     Citation Subset:  IM    
Copyright Information:
© 2013 International Society for Sexual Medicine.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Combined Modality Therapy
Diabetic Neuropathies / complications
Erectile Dysfunction / etiology,  therapy*
Humans
Male
Phosphodiesterase 5 Inhibitors / contraindications,  therapeutic use
Prostatectomy / adverse effects
Renal Dialysis
Spinal Cord Injuries / complications
Vacuum
Chemical
Reg. No./Substance:
0/Phosphodiesterase 5 Inhibitors
Comments/Corrections
Comment In:
J Urol. 2013 Dec;190(6):2145   [PMID:  24209538 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Statistical optimization of culture conditions for biomass production of probiotic gut-borne Sacchar...
Next Document:  Effects of Hydrogen Bonding on Internal Conversion of GFP-like Chromophores: I. The para-Amino Syste...